-
1 Comment
Synektik S.A. is currently in a long term uptrend where the price is trading 21.0% above its 200 day moving average.
Synektik S.A.'s total revenue sank by 9.4% to $34M since the same quarter in the previous year.
Its net income has increased by 45.5% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 18.5% to $12M since the same quarter in the previous year.
Based on the above factors, Synektik S.A. gets an overall score of 3/5.
| Industry | Medical Devices |
|---|---|
| Exchange | WAR |
| CurrencyCode | PLN |
| ISIN | PLSNKTK00019 |
| Sector | Healthcare |
| Target Price | 235.7375 |
|---|---|
| Dividend Yield | 3.5% |
| Market Cap | 2B |
| PE Ratio | 24.14 |
| Beta | 1.4 |
Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as researches, produces, and sells radiopharmaceutical products used in diagnostics for oncology. In addition, the company operates a research laboratory for diagnostic imaging systems and a service center for medical equipment. Further, it offers maintenance services for medical equipment, as well as acceptance and specialist tests. The company was founded in 2001 and is based in Warsaw, Poland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SNT.WAR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
